Navigation Links
Early Safety Results Promising for Phase I/II Trial of Gene Therapy Treatment of Hemophilia B
Date:12/6/2010

ts liver cells but does not integrate into the patient's DNA. Participants received no immune suppressing drugs prior to infusion of the experimental vector.

Results so far suggest the experimental vector does not trigger the T-cell mediated immune response seen in a previous hemophilia B gene therapy trial.

The third and highest dose of the novel gene-vector combination is scheduled to be infused into the fifth and sixth study participants by mid-January. Investigators will then decide whether to expand the trial to include four more adults with severe hemophilia B. Study participants were all recruited at UCL/Royal Free Hospital through the efforts of co-author Edward G.D. Tuddenham, M.D.

Davidoff and Nathwani noted that hemophilia B has been the main focus of gene therapy efforts for disorders affecting the liver because the threshold required for therapeutic effect is modest. In patients with severe hemophilia B whose baseline level of Factor IX is less than 1 percent, generating expression of just 5 percent has the potential to dramatically affect their quality of life, reducing disabling and painful episodes of bleeding and eliminating the need for costly infusions of the protein.

Factor IX is needed for normal clot formation. A mutation in the gene that carries instructions for assembling the protein leaves about 1 in 30,000 individuals at risk for disabling episodes of internal and external bleeding. The gene is carried on the X chromosome, and the disorder is almost exclusively a male disease.

The trial vector was made at the Children's Good Manufacturing Practices (GMP), LLC, facility, on the St. Jude campus. The GMP operates under government-approved manufacturing guidelines and produces the highly specialized medicines and vaccines that pharmaceutical companies are reluctant to pursue.

The other authors are Cecilia Rosales and Jenny McIntosh (both of UCL); Anne Riddell (KD Haemophilia Centre and Thrombosis Unit
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. LSU’s Jayne Garno receives early career award from President
2. NOVAVAX Awarded Nearly $1 Million in Grants from IRS Under Qualifying Therapeutic Discovery Project
3. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
4. Osteotech Announces Early Termination of HSR Waiting Period
5. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
6. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
7. Deloitte Recap Honors Sanofi-aventis and Exelixis With the Allicense 2010 Breakthrough Alliance Award for Early-Stage Collaboration in Cancer
8. West Michigan Launches $10 Million Early Stage Venture Fund to Support Life Science & Technology
9. New Study Demonstrates Clinical Validity of EarlyCDT-Lung™
10. Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer
11. New test takes guesswork out of diagnosing early stage Alzheimers disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015  Natera, Inc. (Nasdaq: NTRA ), ... of circulating cell-free DNA, today announced that it will ... 2015 after the market close on August 12, 2015. ... 1:30 p.m. PT (4:30 p.m. ET) to discuss its ... 2015 Results Conference Call  Date: , Wednesday, August 12, ...
(Date:8/3/2015)... , Aug. 3, 2015  Halozyme Therapeutics, Inc. ... Conference Call for the second quarter 2015 on Monday, ... Dr. Helen Torley , president and chief executive ... post-market, Halozyme will release financial results for the second ... live through the "Investors" section of Halozyme,s corporate website ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Benzene is processed to get such derivatives as ethylbenzene, a precursor to styrene, ... used within the automotive industry for the production of tyres and other components. ...
(Date:8/3/2015)... , August 3, 2015 ... the commercialization of its Bio-electrical Signal Therapy device ("BST ... treatment of hard to heal chronic wounds, today announced ... with Chemipal, an Israeli distributor specializing in medical devices, ... Chemipal is a 70 years old, sales, ...
Breaking Biology Technology:Natera to Release Second Quarter 2015 Results on August 12, 2015 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3
... ARBOR, Mich.---A delicate balance of atomic forces can be ... size---an attribute that,s important for many nanotech applications but ... The same type of forces are at work ... inorganic supercluster structures in this research are in many ...
... announced today they have been named to the prestigious 30th ... entrepreneurial and fastest growing companies in America. The 2011 Inc. ... past three years.  HumanTouch is ranked 203 on this list. ... representatives of the Inc. 500 such as Zappos, Patagonia, Intuit ...
... 2011 Biotechnology leader Divine Skin Inc. (DSKX) posted ... quarter. The expanding innovator of personal care solutions credits ... sales, which are 79 percent ahead of the same ... has been keeping up with demand," said Divine Skin ...
Cached Biology Technology:Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 3
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... , July 7, 2015  Based on ... Frost & Sullivan recognizes Credence ID, LLC with ... Entrepreneurial Company of the Year Award. Credence ID ... aid in its mission of offering enrollment and ... globally. As Credence ID was formed by experts ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) has ... Market by Application, Technology, Function & Geography - Global ... The next generation biometrics market is expected to ... 17.9% between 2015 and 2020 Travel & ... Safran SA ( France ), NEC ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3
... particularly carbon dioxide (CO2), have been associated with ... grasslands, drainage of the land, and land use ... have led scientists to measure soil organic carbon ... to evaluate how changes in tillage practices affect ...
... major challenges facing the international community in the coming century. ... the distribution of the sea ice, and has led to ... close connection between the Arctic climate and our own. The ... to the polar front extending south, for example. Researchers ...
... tympanoplasty can be performed successfully in 95 percent of ... study in the February 2013 issue of OtolaryngologyHead ... frequently performed procedure with varying reported success rates ranging ... membrane repair success in children is often perceived as ...
Cached Biology News:New protocol recommendations for measuring soil organic carbon sequestration 2New protocol recommendations for measuring soil organic carbon sequestration 3New protocol recommendations for measuring soil organic carbon sequestration 4Aarhus University builds research station in North Greenland 2Aarhus University builds research station in North Greenland 3
... a clone of the human Topoisomerase II gene. ... the topological state of nucleic acids by passing ... which generates a separate DNA helix (1,2) . ... mechanism, the enzyme can relax negatively or positively ...
RNase-Free DNase 50 l...
supplied with 10x reaction buffer...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
Biology Products: